Search clinical trials for: 14C-BI 409306

Total 3910 results

Arthrosi Therapeutics
Celerion

Completed

Single-dose AME Study With [14C]AR882 in Healthy Male Subjects

Healthy Volunteers

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor

Solid Tumor

China
Jiangsu vcare pharmaceutical technology co., LTD

Completed

The Mass Balance and Biotransformation of [14C] Vicagrel in Healthy Man

Healthy Male Adult

China
Enyo Pharma

Completed

Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose

Healthy

Netherlands
Corcept Therapeutics

Completed

A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body

Healthy

United Kingdom
Acacia Pharma Ltd

Completed

Mass-balance Study of [14C]-APD421 in Healthy Volunteers

Post-operative Nausea and Vomiting

Netherlands
EA Pharma Co., Ltd.

Completed

A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants

Healthy Male Participants

United Kingdom
AstraZeneca

Completed

Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931

Healthy

United Kingdom
Pfizer
Syneos Health

Completed

A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers

Carcinoma, Non-Small-Cell Lung

United States
Boehringer Ingelheim

Completed

BI 894999 First in Human Dose Finding Study in Advanced Malignancies

Neoplasms | NUT Carcinoma

United States, Spain, Belgium, Germany, France, Korea, Republic of
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 1015550 Are Taken up in the Body of Healthy Japanese Men

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body

Healthy

China
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether Food Affects the Amount of BI 894416 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

Pancreatic Neoplasms

Austria, Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein

Healthy

Belgium
Boehringer Ingelheim

Completed

Dose Finding Study of BI 836880 in Patients With Solid Tumors

Neoplasms

Germany, France
Boehringer Ingelheim

Completed

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body

Healthy | Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body

Healthy | Chronic Kidney Disease

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Netherlands
Boehringer Ingelheim

Completed

Weekly BI 836880 in Patients With Advanced Solid Tumors

Neoplasms

Spain, France
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours

Neoplasms

Hungary
Boehringer Ingelheim

Completed

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse

Leukemia, Myeloid, Acute

United States
Boehringer Ingelheim

Completed

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Wet Macular Degeneration

Austria, Germany, Hungary
Boehringer Ingelheim

Completed

Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

BI 811283 in Various Solid Tumours

Neoplasms

Germany
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine
Sunshine Lake Pharma Co., Ltd.

Completed

ADME Study of [14C] Yiqibuvir in Healthy Male Subjects

Healthy Male Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers

Lymphoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

ADME Study of [14C]-Jaktinib in Healthy Male Subjects

Healthy Adult Male Volunteers

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of [14C]IBI351 in Healthy Subjects

Healthy Subjects

China
RAPT Therapeutics, Inc.

Completed

Study of RPT193 in Healthy Adult Male Subjects

Healthy Male Subjects

United States
Guangdong Raynovent Biotech Co., Ltd

Completed

Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in China

Pharmacokinetics

China
Genor Biopharma Co., Ltd.

Completed

A Study of [14C]GB491 in Male Healthy Subjects

Breast Cancer | Nonsmall Cell Lung Cancer

China
PMV Pharmaceuticals, Inc

Completed

AME Study of [14C]-PC14586 in Healthy Male Participants

Healthy Male Volunteers

United States
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers

Healthy Adult Male Volunteers

China
4SC AG

Completed

A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat

Mycosis Fungoides | Sezary Syndrome | Cutaneous T Cell Lymphoma

United Kingdom
Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Completed

A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers

Healthy Volunteers

China
Vigonvita Life Sciences
Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Completed

Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects

Healthy Male Subjects

China
Corcept Therapeutics

Completed

Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants

Healthy

United Kingdom
AstraZeneca

Withdrawn

Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion

Healthy

United States
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Not yet recruiting

A Follow-up Study to Test Long-term Treatment With BI 1015550 in People With Pulmonary Fibrosis Who Took Part in a Previous Study With BI 1015550 (FIBRONEER™-ON)

Idiopathic Pulmonary Fibrosis | Progressive Pulmonary Fibrosis
Boehringer Ingelheim

Active, not recruiting

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Geographic Atrophy

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1595043 is Taken up in the Body When Given With or Without Food

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study to Test How Food Influences the Amount of BI 1323495 in the Blood of Healthy Men

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems

Healthy | Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 690517 in Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.

Healthy

United Kingdom
Boehringer Ingelheim

Terminated

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Belgium, Bulgaria, Germany, Greece, Netherlands, Poland, Portugal, Spain

3

Subscribe